Conference Presentation, Keynote, Lecture
The 5 Revolutions in Cancer Treatment
- Five distinct approaches are identified as necessary to eradicate cancer: genomically targeted therapy, cancer immunotherapy (including checkpoint inhibitors, CAR-T, and vaccines), exploitation of extra-chromosomal DNA (ECDNA), and nutritional strategies, aiming to integrate these into patient-centered care.
- Statistics indicate that over half of patients present with advanced or late-stage disease, which is characterized by aggressiveness and constant mutation, necessitating continuous evolutionary developments in treatment to maintain efficacy.
- Genomically targeted therapy, originating in the 1990s with the approval of Herceptin and Gleevec, has enabled unprecedented outcomes, such as the disappearance of 15 to 20 brain lesions in a metastatic lung cancer patient over ten months.
- Immunotherapy has achieved a critical milestone where approximately one-third of metastatic melanoma patients reach the five-year survival mark, though the speaker notes the majority of patients across solid tumor types still do not respond.
- Future work is required to identify specific biomarkers and optimal drug combinations to increase five-year survival rates closer to 100 percent and overcome current resistance to checkpoint inhibitors.
- Extra-chromosomal DNA (ECDNA) is identified as a potential fourth revolution, found in over 50% of solid tumor types, offering a new mechanism to target unique enzymatic vulnerabilities and complement existing therapies.
- Nutrition is positioned as the fifth revolution, with potential impacts comparable to drugs, focusing on plant-based calorie-restricted diets, targeting tumor glucose-glutamine dependency, and microbiome exploration.
- While specific cases like a lymphoma patient recovering after a 21-day water-only fast illustrate potential, the speaker emphasizes that randomized controlled studies are required due to the complexity of the field.
- The continuation of intractinib work originally started at Ignita is now being pursued by Roche, the world's largest oncology company.
- The overarching prediction is that successfully integrating these five revolutions will provide the hope of eventually erasing cancer.